Pregnancy and COVID – 19: A Review of Tests, Medications and Vaccines

Jana Abd Al-Salam, Hiba Ibrahim, Ahmad Shoujaa

Abstract


Coronavirus disease 19 (COVID-19) has recently emerged as a major threat to human health. Infections range from asymptomatic to severe (increased respiratory rate, hypoxia, significant lung involvement on imaging) or critical (multi-organ failure or dysfunction or respiratory failure requiring mechanical ventilation or high-flow nasal cannula). Current evidence suggests that pregnancy women are at increased risk of severe disease, specifically the need for hospitalization, ICU admission, and mechanical ventilation and the already complex management of infection with an emerging pathogen may be further complicated by pregnancy. The goal of this review is to provide an overview of what is known about the clinical course of COVID-19 in pregnancy, drawing on (a) knowledge of immunologic and physiologic changes in pregnancy and how these might impact infection with COVID-19, (b) experience with other coronaviruses such as SARS and MERS and we also briefly summarize considerations in management of severe COVID-19 in pregnancy

Keywords


COVID-19, pregnancy, tests, medications, vaccines

Full Text:

PDF

References


Sutton, D., Fuchs, K., D’alton, M. and Goffman, D. "Universal screening for SARS-CoV-2 in women admitted for delivery." New England Journal of Medicine 382.22 (2020): 2163-2164.

Breslin, N., Baptiste, C. and Gyamfi-Bannerman, C., et al. "COVID-19 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals." Am J Obstet Gynecol MFM 100118 (2020).

Knight, M., Bunch, K., Vousden, N., Morris, E., Simpson, N., Gale, C., O’Brien, P., Quigley, M., Brocklehurst, P. and Kurinczuk, J. J. "Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study." bmj 369 (2020).

Hantoushzadeh, S., Shamshirsaz, A. A., Aleyasin, A. et al. "Maternal death due to COVID-19." American journal of obstetrics and gynecology (2020).

Lund, C. J. and Donovan, J. C. "Blood volume during pregnancy: significance of plasma and red cell volumes." American journal of obstetrics and gynecology 98.3 (1967): 393-403.

Poltronieri, P., Sun, B. and Mallardo, M. "RNA viruses: RNA roles in pathogenesis, coreplication and viral load." Current genomics 16 (2015): 327-335.

Bridge, J. A. "Reverse transcription–polymerase chain reaction molecular testing of cytology specimens: Pre‐analytic and analytic factors." Cancer cytopathology 125.1 (2017): 11-19.

Raeisossadati, M. J., Danesh, N. M., Borna, F., Gholamzad, M., Ramezani, M., Abnous, K. and Taghdisi, S. M. "Lateral flow based immunobiosensors for detection of food contaminants." Biosensors and Bioelectronics 86 (2016): 235-246.

O'Connell, M. R. "Molecular mechanisms of RNA targeting by Cas13-containing type VI CRISPR–Cas systems." Journal of molecular biology 431.1 (2019): 66-87.

Richardson, S., Hirsch, J. S., Narasimhan, M., et al. "Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area." Jama (2020).

Kupferschmidt, K. and Cohen, J. "Race to find COVID-19 treatments accelerates." Science 367 (2020): 1412-1413.

Sheahan, T. P., Sims, A. C., Zhou, S., et al. "An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice." Science translational medicine 12 (2020).

Furuta, Y., Komeno, T. and Nakamura, T. "Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase." Proceedings of the Japan Academy, Series B 93.7 (2017): 449-463.

Prompetchara, E., Ketloy, C. and Palaga, T. "Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic." Asian Pacific journal of allergy and immunology 38.1 (2020): 1-9.

He, Y., Zhou, Y., Liu, S., Kou, Z., Li, W., Farzan, M. and Jiang, S. "Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine." Biochemical and biophysical research communications 324.2 (2004): 773-781.

Lanese, N. “First coronavirus vaccine trial in the US is recruiting volunteers.” livescience.com (2020).

Middeldorp, S., Coppens, M., van Haaps, T.F., et al. "Incidence of venous thromboembolism in hospitalized patients with COVID‐19." Journal of Thrombosis and Haemostasis (2020).

D’Souza, R., Malhamé, I., Teshler, L., Acharya, G., Hunt, B. J. and McLintock, C. "A critical review of the pathophysiology of thrombotic complications and clinical practice recommendations for thromboprophylaxis in pregnant patients with COVID‐19." Acta obstetricia et gynecologica Scandinavica 99.9 (2020): 1110-1120.

Pierce-Williams, R. A., Burd, J., Felder, L., Khoury, R., et al. "Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study." American journal of obstetrics & gynecology MFM (2020): 100134.

Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. and Cutrell, J. B. "Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review." Jama 323.18 (2020).

Smith, D. D., Pippen, J. L., Adesomo, A. A., Rood, K. M., Landon, M. B. and Costantine, M. M. “Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries.” American journal of perinatology (2020).

Malhamé, I., D'Souza, R. and Cheng, M. P. “The Moral Imperative to Include Pregnant Women in Clinical Trials of Interventions for COVID-19.” Annals of Internal Medicine (2020).


Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Annals of Pharma Research

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.